Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Matthew J Sale,
Emma Minihane,
Noel R Monks,
Rebecca Gilley,
Frances M Richards,
Kevin P Schifferli,
Courtney L Andersen,
Emma J Davies,
Mario Aladren Vicente,
Eiko Ozono,
Aleksandra Markovets,
Jonathan R Dry,
Lisa Drew,
Vikki Flemington,
Theresa Proia,
Duncan I Jodrell,
Paul D Smith,
Simon J Cook
Dec 16, 2019
BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops. Despite increasing the abundance of pro-apoptotic BIM and BMF, ERK1/2 pathway inhibition is predominantly cytostatic, reflecting residual...